Digitisation | November 03, 2023
Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Aster Whitefield will be Aster's 3 rd multi-specialty hospital in Bengaluru and overall 19th hospital in India
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The companies plan to start a pivotal Phase 3 trial in the coming months
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
Subscribe To Our Newsletter & Stay Updated
